Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | NPC1 | O15118 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.61 |
| ▸ | CTSG | P08311 | 1/20 | 0.61 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.61 |
| ▸ | CMA1 | P23946 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25970084 | 0.98 | SMN1; SMN2 (0.96) | SMN1; SMN2HPGDNPC1RAB9ANPSR1 | |
| SCHEMBL15577818 | 0.93 | SMN1; SMN2 (0.87) | SMN1; SMN2HPGDNPC1RAB9ANPSR1 | |
| SCHEMBL30910449 | 0.93 | SMN1; SMN2 (0.87) | SMN1; SMN2HPGDNPC1RAB9ANPSR1 | |
| SCHEMBL31746985 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2HPGDNPC1RAB9ANPSR1 | |
| SCHEMBL28984149 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2HPGDNPC1RAB9ANPSR1 | |
| SCHEMBL18671529 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2HPGDNPC1RAB9ANPSR1 | |
| SCHEMBL18671548 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2HPGDNPC1RAB9ANPSR1 | |
| SCHEMBL10064731 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2HPGDNPC1RAB9ANPSR1 | |
| SCHEMBL16361209 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2HPGDNPC1RAB9ANPSR1 | |
| SCHEMBL3499586 | 0.91 | SMN1; SMN2 (0.83) | SMN1; SMN2HPGDNPC1RAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230260787-A1 | COMPOSITION FOR FORMING PROTECTIVE FILM AGAINST ALKALINE AQUEOUS HYDROGEN PEROXIDE, SUBSTRATE FOR PRODUCING SEMICONDUCTOR APPARATUS, METHOD FOR FORMING PROTECTIVE FILM, AND METHOD FOR FORMING PATTERN | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-08-17 | — | — | US | disclosed |
| US-11311624-B2 | Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-04-26 | — | — | US | disclosed |
| US-20200164081-A1 | INHIBITORS OF MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR AND MEK/PI3K/mTOR BIOLOGICAL PATHWAYS AND METHODS FOR IMPROVING LYMPHATIC UPTAKE, BIOAVAILABILITY, AND SOLUBILITY OF THERAPEUTIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-28 | — | — | US | disclosed |
| WO-2019032640-A1 | INHIBITORS OF MEK/PI3K, JAK/MEK, JAK/PI3K/MTOR AND MEK/PI3K/MTOR BIOLOGICAL PATHWAYS AND METHODS FOR IMPROVING LYMPHATIC UPTAKE, BIOAVAILABILITY, AND SOLUBILITY OF THERAPEUTIC COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311624-B2 | Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds | MTOR, JAK2, JAK1 | SMN1; SMN2 2942/4885HPGD 1961/4885NPC1 1233/4885 |
| US-20200164081-A1 | INHIBITORS OF MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR AND MEK/PI3K/mTOR BIOLOGICAL PATHWAYS AND METHODS FOR IMPROVING LYMPHATIC UPTAKE, BIOAVAILABILITY, AND SOLUBILITY OF THERAPEUTIC COMPOUNDS | MTOR, JAK2, JAK1 | SMN1; SMN2 2942/4885HPGD 1961/4885NPC1 1233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.